NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Rhea-AI Summary
NANOBIOTIX (NASDAQ: NBTX) will report its fourth quarter and full year 2025 operational and financial results on March 31, 2026, after U.S. market close. A conference call and webcast will be held on April 1, 2026 at 8:00 AM EDT / 2:00 PM CEST.
Laurent Levy, CEO, and Bart van Rhijn, chief financial and business officer, will review year-end results and provide a business update. Webcast replay will be archived on the company website; investors may submit questions in advance via email.
Positive
- None.
Negative
- None.
News Market Reaction – NBTX
In the Mar 27 session, NBTX declined 4.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Takeover speculation response | Neutral | +4.7% | Company addressed media speculation about a potential public take-over. |
| Mar 12 | Capital structure update | Neutral | +4.9% | Reported shares outstanding and theoretical vs exercisable voting rights. |
| Feb 25 | Investor conferences | Neutral | +1.4% | Announced participation in multiple healthcare and biotech investor conferences. |
| Feb 17 | Capital structure update | Neutral | +1.1% | Disclosed updated share count and voting rights as of January 31, 2026. |
| Jan 13 | Capital structure update | Neutral | +0.7% | Reported shares outstanding and voting rights as of December 31, 2025. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent routine disclosures (voting rights, conference participation, clarification press releases) have generally coincided with small positive price reactions.
Over recent months, NANOBIOTIX has mainly issued routine corporate updates. Multiple disclosures of share capital and voting rights on Dec 31, 2025, Jan 31, 2026, and Feb 28, 2026 all saw modest positive price reactions. The company also highlighted participation in investor conferences in late February, again with a mild uptick. Most recently, a statement on Mar 25, 2026 refuting media speculation about a potential take-over also aligned with a positive move. Today’s earnings date announcement fits this pattern of informational communication.
Key Terms
nanoparticle-based medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market.
This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and business officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2025 before taking questions from participants.
Details of the call are as follows:
Webcast link: click here
Conference call link: click here
Details of the call are also available in the investors section of the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior the event start. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.
Participants are invited to email their questions in advance to investors@nanobiotix.com.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2026-03-26 -- NBTX -- 4Q & FY25 STD -- FINAL
